2424:
37:
582:
is a rare but known serious risk characterized by a severe drop in platelets circulating in the blood. Abciximab induced thrombocytopenia is usually rapid occurring hours after administration but may occur up to 16 days later. Transfusing platelets is the only known treatment for abciximab-induced
535:
Abciximab is indicated for use in individuals undergoing percutaneous coronary intervention (angioplasty with or without stent placement). The use of abciximab in this setting is associated with a decreased incidence of ischemic complications due to the procedure and a decreased need for repeated
559:
of about ten minutes, with a second phase half-life of about 30 minutes. However, its effects on platelet function can be seen for up to 48 hours after the infusion has been terminated, and low levels of glycoprotein IIb/IIIa receptor blockade are present for up to 15 days after the infusion is
1836:
1829:
1822:
543:. It is not the appropriate drug of choice if a patient is scheduled for an emergency surgery (i.e., heart surgery) because bleeding time may take about 12 hours to normalize. Pediatric uses include treatment of
750:"Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial"
519:, it may occupy some receptors for weeks. In practice, platelet aggregation gradually returns to normal about 96 to 120 hours after discontinuation of the drug. Abciximab is made from the
572:
Many of the side effects of abciximab are due to its anti-platelet effects which increase the risk of bleeding. The most common type of bleeding due to abciximab is gastrointestinal
174:
200:
452:
2464:
2459:
601:
Toronto Notes: Comprehensive medical reference and review for the
Medical Council of Canada Qualifying Exam Part I and the United States Medical Licensing Exam Step 2
120:
583:
thrombocytopenia, but this therapy may have limited effectiveness because the drug may bind and inhibit the receptors on the newly transfused platelets.
2444:
1666:
904:
51:
996:
2378:
1780:
675:
608:
824:
Webb GJ, Swinburn JM, Grech H (2011). "Profound delayed thrombocytopenia presenting 16 days after
Abciximab (Reopro) administration".
1151:
170:
947:
473:
1761:
1169:
1142:
882:
509:
230:
138:
2449:
1814:
1096:
709:"Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty"
489:
897:
2414:
1909:
1380:
329:
2395:
1845:
1797:
1471:
1191:
653:
157:
1553:
1527:
1519:
2454:
2034:
2029:
890:
624:
520:
2383:
1785:
185:
2290:
1134:
1058:
540:
477:
378:
1662:
481:
1724:
1303:
1258:
1114:
273:
192:
63:
44:
690:
2266:
2168:
2067:
1938:
1405:
849:
515:
While abciximab has a short plasma half-life, due to its strong affinity for its receptor on the
1567:
970:
965:
1649:
1420:
1410:
1400:
1395:
1390:
1365:
938:
925:
917:
841:
806:
771:
748:
Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, et al. (September 2003).
730:
604:
258:
245:
102:
68:
2075:
1623:
1454:
1415:
1385:
833:
798:
761:
720:
579:
544:
394:
282:
338:
2428:
1427:
493:
871:
789:
Usta C, Turgut NT, Bedel A (November 2016). "How abciximab might be clinically useful".
2389:
2044:
1791:
1318:
1004:
913:
766:
749:
561:
524:
2438:
2360:
2319:
2129:
1963:
1748:
1718:
1308:
1293:
1288:
1249:
921:
603:(32nd ed.). Toronto, Ontario, Canada.: Toronto Notes for Medical Students, Inc.
853:
2355:
2246:
2241:
2226:
2183:
2124:
2114:
2099:
2094:
1738:
1708:
1686:
1681:
1654:
1603:
1582:
1432:
1371:
1327:
1204:
1147:
1086:
1081:
1062:
960:
929:
213:
208:
56:
837:
802:
130:
2339:
2305:
2271:
2261:
2236:
2139:
2134:
2089:
2084:
2080:
2057:
2008:
1968:
1895:
1608:
1536:
1505:
1437:
1338:
1332:
1322:
1225:
1019:
1009:
725:
708:
539:
Research also shows that this drug can be of use for patients with diabetes and
497:
2334:
2251:
2231:
2210:
2205:
2173:
2109:
2104:
1998:
1993:
1983:
1978:
1973:
1958:
1953:
1924:
1890:
1713:
1630:
1613:
1598:
1577:
1562:
1557:
1500:
1485:
1459:
1449:
1444:
1298:
1267:
1199:
1179:
1157:
1046:
1030:
1026:
975:
573:
536:
coronary artery revascularization in the first month following the procedure.
505:
433:
313:
2276:
2256:
2200:
2188:
2178:
2153:
2119:
2013:
2003:
1988:
1874:
1869:
1701:
1696:
1676:
1671:
1618:
1572:
1546:
1541:
1490:
1348:
1271:
1235:
1209:
1174:
1162:
1124:
1119:
1109:
1071:
1041:
1036:
1014:
980:
556:
124:
845:
810:
775:
645:
734:
560:
terminated. Abciximab does not require dose adjustments for patients with
527:
that targets the glycoprotein IIb/IIIa receptor on the platelet membrane.
28:
2195:
1495:
1480:
1313:
1284:
1275:
1263:
1230:
1076:
516:
501:
293:
152:
302:
1766:
1756:
1733:
1531:
1360:
1104:
84:
36:
17:
1728:
369:
358:
990:
676:"International Nonproprietary Names for Pharmaceutical Substances"
76:
72:
1854:
1635:
349:
239:
89:
1818:
886:
252:
164:
147:
1848:
for bone, musculoskeletal, circulatory, and neurologic systems
459:
2412:
2348:
2327:
2318:
2298:
2289:
2219:
2161:
2152:
2066:
2043:
2022:
1946:
1937:
1917:
1908:
1883:
1862:
1853:
1747:
1648:
1591:
1518:
1470:
1359:
1347:
1257:
1248:
1218:
1190:
1133:
1095:
1057:
989:
946:
937:
432:
393:
388:
368:
348:
328:
312:
292:
272:
267:
229:
224:
199:
184:
137:
119:
111:
101:
96:
83:
62:
50:
43:
634:. U.S. Food and Drug Administration. August 2019.
508:) formation within the coronary artery. It is a
281:
169:
1830:
898:
504:from sticking together and causing thrombus (
8:
156:
27:
2324:
2295:
2158:
1943:
1914:
1859:
1837:
1823:
1815:
1356:
1254:
943:
905:
891:
883:
35:
765:
724:
474:glycoprotein IIb/IIIa receptor antagonist
337:
2465:Drugs developed by Eli Lilly and Company
2460:Drugs developed by Johnson & Johnson
2419:
592:
301:
26:
377:
129:
7:
878:. U.S. National Library of Medicine.
212:
791:International Journal of Cardiology
713:The New England Journal of Medicine
357:
767:10.1161/01.CIR.0000087601.45803.86
656:from the original on 20 April 2010
25:
707:EPIC Investigators (April 1994).
2445:Glycoprotein IIb/IIIa inhibitors
2422:
1520:Direct thrombin (IIa) inhibitors
948:Glycoprotein IIb/IIIa inhibitors
632:Janssen Pharmaceutical Companies
411:
405:
1143:Thromboxane synthase inhibitors
510:glycoprotein IIb/IIIa inhibitor
490:platelet aggregation inhibitor
423:
417:
399:
1:
492:mainly used during and after
1381:Low-molecular-weight heparin
1192:Phosphodiesterase inhibitors
1105:Acetylsalicylic acid/Aspirin
838:10.3109/09537104.2010.518324
803:10.1016/j.ijcard.2016.07.213
726:10.1056/NEJM199404073301402
2481:
389:Chemical and physical data
2373:
1775:
1353:(with some II inhibition)
689:(4). 1993. Archived from
449:
34:
876:Drug Information Portal
555:Abciximab has a plasma
2291:Angiogenesis inhibitor
1663:Plasminogen activators
1135:Thromboxane inhibitors
1059:Prostaglandin analogue
541:chronic kidney disease
2450:Monoclonal antibodies
1725:serine endopeptidases
1259:Vitamin K antagonists
484:under the trade name
115:Abcixifiban, c7E3 Fab
1472:Direct Xa inhibitors
1304:Ethyl biscoumacetate
1170:Receptor antagonists
683:WHO Drug Information
478:Janssen Biologics BV
1115:Carbasalate calcium
531:Indications for use
480:and distributed by
248:(Prescription only)
45:Monoclonal antibody
31:
2400:Never to phase III
2169:Anti-amyloid drugs
1802:Never to phase III
1650:Thrombolytic drugs
1366:glycosaminoglycans
939:Antiplatelet drugs
926:antiplatelet drugs
625:"ReoPro Abciximab"
2410:
2409:
2369:
2368:
2314:
2313:
2285:
2284:
2148:
2147:
1933:
1932:
1904:
1903:
1812:
1811:
1644:
1643:
1514:
1513:
1244:
1243:
696:on June 27, 2004.
610:978-1-927363-26-3
467:
466:
256:
243:
167:
150:
16:(Redirected from
2472:
2427:
2426:
2425:
2418:
2325:
2296:
2159:
2076:Alacizumab pegol
1944:
1915:
1860:
1839:
1832:
1825:
1816:
1624:Drotrecogin alfa
1604:Antithrombin III
1455:Dermatan sulfate
1428:Oligosaccharides
1357:
1255:
991:ADP receptor/P2Y
944:
907:
900:
893:
884:
879:
858:
857:
821:
815:
814:
786:
780:
779:
769:
745:
739:
738:
728:
704:
698:
697:
695:
680:
672:
666:
665:
663:
661:
642:
636:
635:
629:
621:
615:
614:
597:
580:Thrombocytopenia
551:Pharmacokinetics
545:Kawasaki disease
523:fragments of an
496:procedures like
476:manufactured by
463:
462:
455:
444:
442:
425:
419:
413:
407:
401:
381:
361:
341:
305:
285:
254:
251:
241:
238:
216:
177:
166:
163:
160:
149:
146:
133:
39:
32:
30:
21:
2480:
2479:
2475:
2474:
2473:
2471:
2470:
2469:
2455:Janssen Biotech
2435:
2434:
2433:
2423:
2421:
2413:
2411:
2406:
2405:
2390:Clinical trials
2365:
2344:
2310:
2281:
2215:
2144:
2062:
2039:
2018:
1929:
1910:Musculoskeletal
1900:
1879:
1849:
1843:
1813:
1808:
1807:
1792:Clinical trials
1771:
1743:
1653:
1640:
1587:
1510:
1466:
1369:
1364:
1352:
1343:
1319:1,3-Indandiones
1261:
1240:
1214:
1186:
1129:
1091:
1053:
1005:Thienopyridines
994:
985:
933:
914:Antithrombotics
911:
870:
867:
862:
861:
823:
822:
818:
788:
787:
783:
760:(11): 1316–23.
747:
746:
742:
706:
705:
701:
693:
678:
674:
673:
669:
659:
657:
644:
643:
639:
627:
623:
622:
618:
611:
599:
598:
594:
589:
570:
553:
533:
494:coronary artery
458:
456:
453:(what is this?)
450:
440:
438:
428:
422:
416:
410:
404:
384:
364:
344:
324:
308:
288:
263:
220:
187:
180:
23:
22:
15:
12:
11:
5:
2478:
2476:
2468:
2467:
2462:
2457:
2452:
2447:
2437:
2436:
2432:
2431:
2408:
2407:
2404:
2403:
2402:
2401:
2398:
2387:
2381:
2375:
2374:
2371:
2370:
2367:
2366:
2364:
2363:
2358:
2352:
2350:
2346:
2345:
2343:
2342:
2337:
2331:
2329:
2322:
2316:
2315:
2312:
2311:
2309:
2308:
2302:
2300:
2293:
2287:
2286:
2283:
2282:
2280:
2279:
2274:
2269:
2264:
2259:
2254:
2249:
2244:
2239:
2234:
2229:
2223:
2221:
2217:
2216:
2214:
2213:
2208:
2203:
2198:
2193:
2192:
2191:
2186:
2181:
2176:
2165:
2163:
2156:
2150:
2149:
2146:
2145:
2143:
2142:
2137:
2132:
2127:
2122:
2117:
2112:
2107:
2102:
2097:
2092:
2087:
2078:
2072:
2070:
2064:
2063:
2061:
2060:
2055:
2049:
2047:
2041:
2040:
2038:
2037:
2032:
2026:
2024:
2020:
2019:
2017:
2016:
2011:
2006:
2001:
1996:
1991:
1986:
1981:
1976:
1971:
1966:
1961:
1956:
1950:
1948:
1941:
1935:
1934:
1931:
1930:
1928:
1927:
1921:
1919:
1912:
1906:
1905:
1902:
1901:
1899:
1898:
1893:
1887:
1885:
1881:
1880:
1878:
1877:
1872:
1866:
1864:
1857:
1851:
1850:
1844:
1842:
1841:
1834:
1827:
1819:
1810:
1809:
1806:
1805:
1804:
1803:
1800:
1789:
1783:
1777:
1776:
1773:
1772:
1770:
1769:
1764:
1759:
1753:
1751:
1745:
1744:
1742:
1741:
1736:
1731:
1721:
1716:
1711:
1706:
1705:
1704:
1699:
1691:
1690:
1689:
1684:
1679:
1674:
1659:
1657:
1646:
1645:
1642:
1641:
1639:
1638:
1633:
1628:
1627:
1626:
1616:
1611:
1606:
1601:
1595:
1593:
1589:
1588:
1586:
1585:
1580:
1575:
1570:
1565:
1560:
1551:
1550:
1549:
1544:
1539:
1524:
1522:
1516:
1515:
1512:
1511:
1509:
1508:
1503:
1498:
1493:
1488:
1483:
1477:
1475:
1468:
1467:
1465:
1464:
1463:
1462:
1457:
1452:
1442:
1441:
1440:
1435:
1425:
1424:
1423:
1418:
1413:
1408:
1403:
1398:
1393:
1388:
1377:
1375:
1354:
1345:
1344:
1342:
1341:
1335:
1330:
1325:
1316:
1311:
1306:
1301:
1296:
1291:
1281:
1279:
1252:
1250:Anticoagulants
1246:
1245:
1242:
1241:
1239:
1238:
1233:
1228:
1222:
1220:
1216:
1215:
1213:
1212:
1207:
1202:
1196:
1194:
1188:
1187:
1185:
1184:
1183:
1182:
1177:
1167:
1166:
1165:
1160:
1155:
1139:
1137:
1131:
1130:
1128:
1127:
1122:
1117:
1112:
1107:
1101:
1099:
1097:COX inhibitors
1093:
1092:
1090:
1089:
1084:
1079:
1074:
1068:
1066:
1055:
1054:
1052:
1051:
1050:
1049:
1044:
1039:
1024:
1023:
1022:
1017:
1012:
1001:
999:
992:
987:
986:
984:
983:
978:
973:
968:
963:
958:
952:
950:
941:
935:
934:
922:anticoagulants
912:
910:
909:
902:
895:
887:
881:
880:
866:
865:External links
863:
860:
859:
816:
781:
740:
719:(14): 956–61.
699:
667:
637:
616:
609:
591:
590:
588:
585:
569:
566:
562:kidney failure
552:
549:
532:
529:
525:immunoglobulin
465:
464:
447:
446:
436:
430:
429:
426:
420:
414:
408:
402:
397:
391:
390:
386:
385:
383:
382:
374:
372:
366:
365:
363:
362:
354:
352:
346:
345:
343:
342:
334:
332:
326:
325:
323:
322:
318:
316:
310:
309:
307:
306:
298:
296:
290:
289:
287:
286:
278:
276:
270:
269:
265:
264:
262:
261:
249:
235:
233:
227:
226:
222:
221:
219:
218:
205:
203:
197:
196:
190:
188:administration
182:
181:
179:
178:
161:
143:
141:
135:
134:
127:
117:
116:
113:
109:
108:
105:
99:
98:
94:
93:
87:
81:
80:
66:
60:
59:
54:
48:
47:
41:
40:
24:
14:
13:
10:
9:
6:
4:
3:
2:
2477:
2466:
2463:
2461:
2458:
2456:
2453:
2451:
2448:
2446:
2443:
2442:
2440:
2430:
2420:
2416:
2399:
2397:
2394:
2393:
2391:
2388:
2385:
2382:
2380:
2377:
2376:
2372:
2362:
2361:Landogrozumab
2359:
2357:
2354:
2353:
2351:
2347:
2341:
2338:
2336:
2333:
2332:
2330:
2326:
2323:
2321:
2320:Growth factor
2317:
2307:
2304:
2303:
2301:
2297:
2294:
2292:
2288:
2278:
2275:
2273:
2270:
2268:
2265:
2263:
2260:
2258:
2255:
2253:
2250:
2248:
2245:
2243:
2240:
2238:
2235:
2233:
2230:
2228:
2225:
2224:
2222:
2218:
2212:
2209:
2207:
2204:
2202:
2199:
2197:
2194:
2190:
2187:
2185:
2182:
2180:
2177:
2175:
2172:
2171:
2170:
2167:
2166:
2164:
2160:
2157:
2155:
2151:
2141:
2138:
2136:
2133:
2131:
2130:Ralpancizumab
2128:
2126:
2123:
2121:
2118:
2116:
2113:
2111:
2108:
2106:
2103:
2101:
2098:
2096:
2093:
2091:
2088:
2086:
2082:
2079:
2077:
2074:
2073:
2071:
2069:
2065:
2059:
2056:
2054:
2051:
2050:
2048:
2046:
2042:
2036:
2033:
2031:
2028:
2027:
2025:
2021:
2015:
2012:
2010:
2007:
2005:
2002:
2000:
1997:
1995:
1992:
1990:
1987:
1985:
1982:
1980:
1977:
1975:
1972:
1970:
1967:
1965:
1964:Ascrinvacumab
1962:
1960:
1957:
1955:
1952:
1951:
1949:
1945:
1942:
1940:
1936:
1926:
1923:
1922:
1920:
1916:
1913:
1911:
1907:
1897:
1894:
1892:
1889:
1888:
1886:
1882:
1876:
1873:
1871:
1868:
1867:
1865:
1861:
1858:
1856:
1852:
1847:
1840:
1835:
1833:
1828:
1826:
1821:
1820:
1817:
1801:
1799:
1796:
1795:
1793:
1790:
1787:
1784:
1782:
1779:
1778:
1774:
1768:
1765:
1763:
1760:
1758:
1755:
1754:
1752:
1750:
1749:Non-medicinal
1746:
1740:
1737:
1735:
1732:
1730:
1726:
1722:
1720:
1719:Streptokinase
1717:
1715:
1712:
1710:
1707:
1703:
1700:
1698:
1695:
1694:
1692:
1688:
1685:
1683:
1680:
1678:
1675:
1673:
1670:
1669:
1668:
1664:
1661:
1660:
1658:
1656:
1655:fibrinolytics
1651:
1647:
1637:
1634:
1632:
1629:
1625:
1622:
1621:
1620:
1617:
1615:
1612:
1610:
1607:
1605:
1602:
1600:
1597:
1596:
1594:
1590:
1584:
1581:
1579:
1576:
1574:
1571:
1569:
1566:
1564:
1561:
1559:
1555:
1552:
1548:
1545:
1543:
1540:
1538:
1535:
1534:
1533:
1529:
1526:
1525:
1523:
1521:
1517:
1507:
1504:
1502:
1499:
1497:
1494:
1492:
1489:
1487:
1484:
1482:
1479:
1478:
1476:
1473:
1469:
1461:
1458:
1456:
1453:
1451:
1448:
1447:
1446:
1443:
1439:
1436:
1434:
1431:
1430:
1429:
1426:
1422:
1419:
1417:
1414:
1412:
1409:
1407:
1404:
1402:
1399:
1397:
1394:
1392:
1389:
1387:
1384:
1383:
1382:
1379:
1378:
1376:
1373:
1367:
1362:
1358:
1355:
1350:
1346:
1340:
1336:
1334:
1331:
1329:
1326:
1324:
1320:
1317:
1315:
1312:
1310:
1309:Phenprocoumon
1307:
1305:
1302:
1300:
1297:
1295:
1294:Coumatetralyl
1292:
1290:
1289:Acenocoumarol
1286:
1283:
1282:
1280:
1277:
1273:
1269:
1265:
1260:
1256:
1253:
1251:
1247:
1237:
1234:
1232:
1229:
1227:
1224:
1223:
1221:
1217:
1211:
1208:
1206:
1203:
1201:
1198:
1197:
1195:
1193:
1189:
1181:
1178:
1176:
1173:
1172:
1171:
1168:
1164:
1161:
1159:
1156:
1153:
1149:
1146:
1145:
1144:
1141:
1140:
1138:
1136:
1132:
1126:
1123:
1121:
1118:
1116:
1113:
1111:
1108:
1106:
1103:
1102:
1100:
1098:
1094:
1088:
1085:
1083:
1080:
1078:
1075:
1073:
1070:
1069:
1067:
1064:
1060:
1056:
1048:
1045:
1043:
1040:
1038:
1035:
1034:
1032:
1028:
1025:
1021:
1018:
1016:
1013:
1011:
1008:
1007:
1006:
1003:
1002:
1000:
998:
995:
988:
982:
979:
977:
974:
972:
969:
967:
964:
962:
959:
957:
954:
953:
951:
949:
945:
942:
940:
936:
931:
927:
923:
919:
918:thrombolytics
915:
908:
903:
901:
896:
894:
889:
888:
885:
877:
873:
869:
868:
864:
855:
851:
847:
843:
839:
835:
831:
827:
820:
817:
812:
808:
804:
800:
797:: 1074–1078.
796:
792:
785:
782:
777:
773:
768:
763:
759:
755:
751:
744:
741:
736:
732:
727:
722:
718:
714:
710:
703:
700:
692:
688:
684:
677:
671:
668:
655:
651:
647:
641:
638:
633:
626:
620:
617:
612:
606:
602:
596:
593:
586:
584:
581:
577:
575:
567:
565:
563:
558:
550:
548:
546:
542:
537:
530:
528:
526:
522:
518:
513:
511:
507:
503:
499:
495:
491:
487:
483:
479:
475:
471:
461:
454:
448:
437:
435:
431:
398:
396:
392:
387:
380:
379:ChEMBL1201584
376:
375:
373:
371:
367:
360:
356:
355:
353:
351:
347:
340:
336:
335:
333:
331:
327:
320:
319:
317:
315:
311:
304:
300:
299:
297:
295:
291:
284:
280:
279:
277:
275:
271:
266:
260:
250:
247:
237:
236:
234:
232:
228:
223:
215:
210:
207:
206:
204:
202:
198:
194:
191:
189:
183:
176:
172:
162:
159:
154:
145:
144:
142:
140:
136:
132:
128:
126:
122:
118:
114:
110:
106:
104:
100:
97:Clinical data
95:
91:
88:
86:
82:
78:
74:
70:
67:
65:
61:
58:
55:
53:
49:
46:
42:
38:
33:
19:
2356:Domagrozumab
2247:Galcanezumab
2242:Fremanezumab
2227:Bapineuzumab
2184:Gantenerumab
2125:Idarucizumab
2115:Etaracizumab
2100:Caplacizumab
2095:Brolucizumab
2052:
1739:Fibrinolysin
1709:Anistreplase
1687:Desmoteplase
1682:Tenecteplase
1583:Ximelagatran
1433:Fondaparinux
1372:antithrombin
1328:Diphenadione
1205:Dipyridamole
1148:Dipyridamole
1087:Treprostinil
1082:Prostacyclin
961:Eptifibatide
955:
875:
832:(4): 302–4.
829:
825:
819:
794:
790:
784:
757:
753:
743:
716:
712:
702:
691:the original
686:
682:
670:
658:. Retrieved
649:
640:
631:
619:
600:
595:
578:
571:
568:Side-effects
554:
538:
534:
514:
485:
469:
468:
457:
451:
231:Legal status
225:Legal status
139:License data
57:Fab fragment
2386:from market
2340:Trevogrumab
2306:Ranibizumab
2272:Solanezumab
2267:Semorinemab
2262:Refanezumab
2237:Eptinezumab
2140:Vanucizumab
2135:Tadocizumab
2090:Bococizumab
2085:Ranibizumab
2081:Bevacizumab
2058:Volociximab
2009:Ramucirumab
1969:Bentracimab
1939:Circulatory
1896:Romosozumab
1846:Monoclonals
1788:from market
1609:Defibrotide
1537:Bivalirudin
1506:Rivaroxaban
1445:Heparinoids
1438:Idraparinux
1339:Tioclomarol
1333:Phenindione
1323:Clorindione
1226:Cloricromen
1020:Ticlopidine
1010:Clopidogrel
872:"Abciximab"
754:Circulation
646:"Abciximab"
500:to prevent
498:angioplasty
445: g·mol
283:143653-53-6
268:Identifiers
193:Intravenous
112:Other names
103:Trade names
2439:Categories
2335:Bimagrumab
2252:Ozanezumab
2232:Crenezumab
2211:Opicinumab
2206:Fulranumab
2174:Aducanumab
2154:Neurologic
2110:Emicizumab
2105:Demcizumab
1999:Nesvacumab
1994:Inclacumab
1984:Evolocumab
1979:Evinacumab
1974:Enoticumab
1959:Alirocumab
1954:Abelacimab
1925:Stamulumab
1891:Blosozumab
1714:Monteplase
1631:Ramatroban
1614:Nafamostat
1599:Abelacimab
1578:Melagatran
1563:Dabigatran
1558:Argatroban
1501:Otamixaban
1486:Betrixaban
1474:("xabans")
1460:Sulodexide
1450:Danaparoid
1421:Tinzaparin
1411:Parnaparin
1406:Nadroparin
1401:Enoxaparin
1396:Dalteparin
1391:Certoparin
1351:inhibitors
1299:Dicoumarol
1200:Cilostazol
1180:Terutroban
1158:Picotamide
1047:Ticagrelor
1031:nucleoside
1027:Nucleotide
997:inhibitors
976:Sibrafiban
587:References
574:hemorrhage
506:blood clot
434:Molar mass
339:X85G7936GV
314:ChemSpider
274:CAS Number
2396:Phase III
2384:Withdrawn
2349:Humanized
2299:Humanized
2277:Tanezumab
2257:Ponezumab
2220:Humanized
2201:Fasinumab
2189:Lecanemab
2179:Donanemab
2120:Faricimab
2068:Humanized
2053:Abciximab
2035:Imciromab
2030:Biciromab
2014:Rinucumab
2004:Orticumab
1989:Icrucumab
1884:Humanized
1875:Denosumab
1870:Burosumab
1798:Phase III
1786:Withdrawn
1702:Urokinase
1697:Saruplase
1677:Reteplase
1672:Alteplase
1619:Protein C
1573:Inogatran
1568:Efegatran
1554:Univalent
1547:Lepirudin
1542:Desirudin
1491:Darexaban
1416:Reviparin
1386:Bemiparin
1349:Factor Xa
1285:Coumarins
1262:(inhibit
1236:Vorapaxar
1210:Triflusal
1175:Terbogrel
1163:Terbogrel
1152:+ aspirin
1125:Triflusal
1120:Indobufen
1110:Aloxiprin
1072:Beraprost
1042:Elinogrel
1037:Cangrelor
1015:Prasugrel
981:Tirofiban
971:Roxifiban
966:Orbofiban
956:Abciximab
826:Platelets
650:Drugs.com
557:half-life
517:platelets
502:platelets
482:Eli Lilly
470:Abciximab
186:Routes of
175:Abciximab
158:Abciximab
131:Monograph
125:Drugs.com
29:Abciximab
2429:Medicine
2196:Erenumab
2045:Chimeric
1528:Bivalent
1496:Edoxaban
1481:Apixaban
1314:Warfarin
1231:Ditazole
1077:Iloprost
1033:analogs
854:40372407
846:21526887
811:27519521
776:12939213
660:13 March
654:Archived
460:(verify)
294:DrugBank
201:ATC code
153:DailyMed
69:Chimeric
1767:Oxalate
1757:Citrate
1734:Brinase
1532:Hirudin
1361:Heparin
1337:Other:
735:8121459
488:, is a
395:Formula
303:DB00054
217:)
211: (
209:B01AC13
173::
155::
2415:Portal
2379:WHO-EM
1781:WHO-EM
1729:Ancrod
1723:Other
1370:(bind
1363:group/
852:
844:
809:
774:
733:
607:
486:ReoPro
370:ChEMBL
359:D02778
259:℞-only
257:
244:
168:
151:
107:Reopro
85:Target
64:Source
18:Reopro
2328:Human
2162:Human
2023:Mouse
1947:Human
1918:Human
1863:Human
1667:r-tPA
1592:Other
1219:Other
850:S2CID
694:(PDF)
679:(PDF)
628:(PDF)
77:human
73:mouse
1855:Bone
1762:EDTA
1693:UPA
1636:REG1
1063:PGI2
924:and
842:PMID
807:PMID
772:PMID
731:PMID
662:2010
605:ISBN
472:, a
409:3229
403:2101
350:KEGG
330:UNII
321:none
195:(IV)
121:AHFS
90:CD41
52:Type
1268:VII
930:B01
928:) (
834:doi
799:doi
795:222
762:doi
758:108
721:doi
717:330
521:Fab
443:.03
441:456
421:673
415:551
246:POM
214:WHO
171:FDA
92:7E3
2441::
2392::
1794::
1727::
1665::
1556::
1530::
1321::
1287::
1274:,
1272:IX
1270:,
1266:,
1264:II
993:12
920:,
874:.
848:.
840:.
830:22
828:.
805:.
793:.
770:.
756:.
752:.
729:.
715:.
711:.
685:.
681:.
652:.
648:.
630:.
576:.
564:.
547:.
512:.
439:47
427:15
253:US
240:UK
165:US
148:US
2417::
2083:/
1838:e
1831:t
1824:v
1652:/
1374:)
1368:/
1278:)
1276:X
1154:)
1150:(
1065:)
1061:(
1029:/
932:)
916:(
906:e
899:t
892:v
856:.
836::
813:.
801::
778:.
764::
737:.
723::
687:7
664:.
613:.
424:S
418:O
412:N
406:H
400:C
255::
242::
123:/
79:)
75:/
71:(
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
